Kye Pharmaceuticals

Kye Pharmaceuticals company information, Employees & Contact Information

Kye is a growth-stage Canadian specialty pharmaceutical company committed to bringing value to Canadians by identifying, licensing and commercializing novel prescription medicines that may not otherwise be available to patients across Canada. At Kye, we recognize the importance of advancing access to innovative healthcare solutions and unlocking better health outcomes for Canadians.

Company Details

Employees
37
Founded
-
Address
2233 Argentia Road, Suite 302 & 302a,canada
Industry
Pharmaceutical Manufacturing
NAICS
Pharmaceutical and Medicine Manufacturing
Medicinal and Botanical Manufacturing
Pharmaceutical Preparation Manufacturing
In-Vitro Diagnostic Substance Manufacturing
Biological Product (except Diagnostic) Manufacturing
HQ
Mississauga, ONTARIO
Looking for a particular Kye Pharmaceuticals employee's phone or email?

Kye Pharmaceuticals Questions

News

Kye Pharmaceuticals Receives Health Canada Approval for New Dosing Guidance for FIRDAPSE ® and an additional Pediatric Indication - PR Newswire Canada

Kye Pharmaceuticals Receives Health Canada Approval for New Dosing Guidance for FIRDAPSE ® and an additional Pediatric Indication PR Newswire Canada

Kye Pharmaceuticals Announces the Approval of DYANAVEL® XR (amphetamine extended-release) Tablets and Oral Suspension for the Treatment of Adults and Children With ADHD - PR Newswire Canada

Kye Pharmaceuticals Announces the Approval of DYANAVEL® XR (amphetamine extended-release) Tablets and Oral Suspension for the Treatment of Adults and Children With ADHD PR Newswire Canada

Kye Pharmaceuticals Announces the Availability of QUILLIVANT® ER Oral Suspension for the Treatment of Children With ADHD - PR Newswire Canada

Kye Pharmaceuticals Announces the Availability of QUILLIVANT® ER Oral Suspension for the Treatment of Children With ADHD PR Newswire Canada

New Drug Submission for AGAMREE® (vamorolone) Accepted for Priority Review by Health Canada for the Treatment of Duchenne Muscular Dystrophy - PR Newswire Canada

New Drug Submission for AGAMREE® (vamorolone) Accepted for Priority Review by Health Canada for the Treatment of Duchenne Muscular Dystrophy PR Newswire Canada

Kye Pharmaceuticals Secures Exclusive License, Supply and Commercialization Agreement with Catalyst Pharmaceuticals for AGAMREE®, a novel treatment for Duchenne muscular dystrophy, in Canada - PR Newswire Canada

Kye Pharmaceuticals Secures Exclusive License, Supply and Commercialization Agreement with Catalyst Pharmaceuticals for AGAMREE®, a novel treatment for Duchenne muscular dystrophy, in Canada PR Newswire Canada

Kye Pharmaceuticals announces approval in Canada for ACCRUFeR® (ferric maltol) for the treatment of iron deficiency anemia in adult patients - PR Newswire Canada

Kye Pharmaceuticals announces approval in Canada for ACCRUFeR® (ferric maltol) for the treatment of iron deficiency anemia in adult patients PR Newswire Canada

ACCRUFeR® (ferric maltol) is now available in Canada as a prescription oral treatment for iron deficiency anemia - PR Newswire Canada

ACCRUFeR® (ferric maltol) is now available in Canada as a prescription oral treatment for iron deficiency anemia PR Newswire Canada

KYE Announces Commercial Availability of CORZYNA™ (ranolazine 500 mg extended-release tablets) - PR Newswire Canada

KYE Announces Commercial Availability of CORZYNA™ (ranolazine 500 mg extended-release tablets) PR Newswire Canada

KYE Pharmaceuticals Announces Approval of CORZYNA™ in Canada (ranolazine extended-release tablets) - PR Newswire Canada

KYE Pharmaceuticals Announces Approval of CORZYNA™ in Canada (ranolazine extended-release tablets) PR Newswire Canada

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant